High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer

Clinical Epigenetics

Karina D. Sorensen¹  Torben F. Orntoft¹  Michael Borre³  Tine Maj Storebjerg³  Christa Haldrup¹  Anne-Sofie Lynnerup³  Soren Hoyer²  Siri H. Strand¹ 

[1] Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark;Department of Histopathology, Aarhus University Hospital, Aarhus, Denmark;Department of Urology, Aarhus University Hospital, Aarhus, Denmark

关键词: Biomarker;    Prognostic;    ERG;    5hmC;    5-hydroxymethylation;    Epigenetics;    DNA methylation;    Prostate cancer;   

Others  :  1234875
DOI  :  10.1186/s13148-015-0146-5

 received in 2015-09-21, accepted in 2015-10-02,  发布年份 2015

【 摘 要 】

Background

Prostate cancer (PC) can be stratified into distinct molecular subtypes based on TMPRSS2-ERG gene fusion status, but its potential prognostic value remains controversial. Likewise, routine clinicopathological features cannot clearly distinguish aggressive from indolent tumors at the time of diagnosis; thus, new prognostic biomarkers are urgently needed. The DNA methylation variant 5-hydroxymethylcytosine (5hmC, an oxidized derivative of 5-methylcytosine) has recently emerged as a new diagnostic and/or prognostic biomarker candidate for several human malignancies. However, this remains to be systematically investigated for PC. In this study, we determined 5hmC levels in 311 PC (stratified by ERG status) and 228 adjacent non-malignant (NM) prostate tissue specimens by immunohistochemical analysis of a tissue microarray, representing a large radical prostatectomy (RP) cohort with long clinical follow-up. We investigated possible correlations between 5hmC and routine clinicopathological variables and assessed the prognostic potential of 5hmC by Kaplan-Meier and uni- and multivariate Cox regression analyses in ERG+ (n = 178) vs. ERG− (n = 133) PCs using biochemical recurrence (BCR) as endpoint.

Results

We observed a borderline significant (p = 0.06) reduction in 5hmC levels in PC compared to NM tissue samples, which was explained by a highly significant (p < 0.001) loss of 5hmC in ERG− PCs. ERG status was not predictive of BCR in this cohort (p = 0.73), and no significant association was found between BCR and 5hmC levels in ERG+ PCs (p = 0.98). In contrast, high 5hmC immunoreactivity was a significant adverse predictor of BCR after RP in ERG− PCs, independent of Gleason score, pathological tumor stage, surgical margin status, and pre-operative prostate-specific antigen (PSA) level (hazard ratio (HR) (95 % confidence interval (CI)): 1.62 (1.15–2.28), p = 0.006).

Conclusions

This is the first study to demonstrate a prognostic potential for 5hmC in PC. Our findings highlight the importance of ERG stratification in PC biomarker studies and suggest that epigenetic mechanisms involving 5hmC are important for the development and/or progression of ERG− PC.

【 授权许可】

   
2015 Strand et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]International Agency for Research on Cancer, W.H.O. Globocan 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed on May 14, 2015.
• [2]Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101.
• [3]Telesca D, Etzioni R, Gulati R: Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008, 64:10-19.
• [4]Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al.: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
• [5]Bostrom, P.J.; Bjartell, A.S.; Catto, J.W.; Eggener, S.E.; Lilja, H.; Loeb, S.; Schalken, J.; Schlomm, T.; Cooperberg, M.R. Genomic predictors of outcome in prostate cancer. European urology 2015: doi:. 10.1016/j.eururo.2015.04.008 webcite
• [6]Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al.: Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012, 44:685-689.
• [7]Brase JC, Johannes M, Mannsperger H, Falth M, Metzger J, Kacprzyk LA, et al.: TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 2011, 11:507. BioMed Central Full Text
• [8]Gasi Tandefelt D, Boormans JL, van der Korput HA, Jenster GW, Trapman J: A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers. Eur Urol 2013, 64:941-950.
• [9]Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA, Tang H, et al.: The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res 2010, 70:8994-9002.
• [10]Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, et al.: Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res 2012, 18:2896-2904.
• [11]Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, et al.: The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008, 13:519-528.
• [12]Vinarskaja A, Schulz WA, Ingenwerth M, Hader C, Arsov C: Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. Urol Oncol 2013, 31:622-627.
• [13]Kron K, Trudel D, Pethe V, Briollais L, Fleshner N, van der Kwast T, et al.: Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clin Cancer Res 2013, 19:3450-3461.
• [14]Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, et al.: Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol 2015, 68(4):555-67.
• [15]Dobosy JR, Roberts JL, Fu VX, Jarrard DF: The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 2007, 177:822-831.
• [16]Chiam K, Ricciardelli C, Bianco-Miotto T: Epigenetic biomarkers in prostate cancer: current and future uses. Cancer Lett 2014, 342:248-256.
• [17]Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, et al.: DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol 2013, 31:3250-3258.
• [18]Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, et al.: Hypermethylation of the GABRE~mir-452~mir-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res 2014, 20:2169-2181.
• [19]Strand SH, Orntoft TF, Sorensen KD: Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci 2014, 15:16544-16576.
• [20]Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al.: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
• [21]Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y: Role of Tet proteins in 5mc to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133.
• [22]Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al.: Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
• [23]He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al.: Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
• [24]Ye C, Li L. 5-hydroxymethylcytosine: a new insight into epigenetics in cancer. Cancer Biol Ther. 2014;15:10–5.
• [25]Iurlaro M, Ficz G, Oxley D, Raiber EA, Bachman M, Booth MJ, et al.: A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation. Genome Biol 2013, 14:R119. BioMed Central Full Text
• [26]Huang Y, Pastor WA, Shen Y, Tahiliani M, Liu DR, Rao A: The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One 2010, 5:e8888.
• [27]Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, et al.: Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011, 2:627-637.
• [28]Haffner MC, Pellakuru LG, Ghosh S, Lotan TL, Nelson WG, De Marzo AM, et al. Tight correlation of 5-hydroxymethylcytosine and polycomb marks in health and disease. Cell Cycle. 2013;12:1835–41.
• [29]Orr BA, Haffner MC, Nelson WG, Yegnasubramanian S, Eberhart CG: Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS One 2012, 7:e41036.
• [30]Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al.: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
• [31]Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, Munzel M, et al.: Low values of 5-hydroxymethylcytosine (5hmc), the "sixth base," are associated with anaplasia in human brain tumors. Int J Cancer 2012, 131:1577-1590.
• [32]Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, et al.: Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci 2012, 103:670-676.
• [33]Li W, Liu M: Distribution of 5-hydroxymethylcytosine in different human tissues. J Nucleic Acids 2011, 2011:870726.
• [34]Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, et al.: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150:1135-1146.
• [35]Liu X, Zhang G, Yi Y, Xiao L, Pei M, Liu S, et al.: Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes. Leuk Lymphoma 2013, 54:2466-2473.
• [36]Uribe-Lewis S, Stark R, Carroll T, Dunning MJ, Bachman M, Ito Y, et al.: 5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer. Genome Biol 2015, 16:69. BioMed Central Full Text
• [37]Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, et al.: Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013, 32:663-669.
• [38]Yang Q, Wu K, Ji M, Jin W, He N, Shi B, et al.: Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol 2013, 9:1607-1616.
• [39]Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, Schackert G, et al.: 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 2011, 71:7360-7365.
• [40]Kroeze LI, Aslanyan MG, van Rooij A, Koorenhof-Scheele TN, Massop M, Carell T, et al.: Characterization of acute myeloid leukemia based on levels of global hydroxymethylation. Blood 2014, 124:1110-1118.
• [41]Globisch D, Munzel M, Muller M, Michalakis S, Wagner M, Koch S, et al.: Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One 2010, 5:e15367.
• [42]Matsuda I, Imai Y, Hirota S: Distinct global DNA methylation status in B-cell lymphomas: immunohistochemical study of 5-methylcytosine and 5-hydroxymethylcytosine. J Clin Exp Hematop 2014, 54:67-73.
• [43]Nestor CE, Ottaviano R, Reddington J, Sproul D, Reinhardt D, Dunican D, et al.: Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res 2012, 22:467-477.
• [44]Nettersheim D, Heukamp LC, Fronhoffs F, Grewe MJ, Haas N, Waha A, et al.: Analysis of TET expression/activity and 5mc oxidation during normal and malignant germ cell development. PLoS One 2013, 8:e82881.
• [45]Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, et al.: Antibody-based detection of erg rearrangement-positive prostate cancer. Neoplasia 2010, 12:590-598.
• [46]Braun M, Goltz D, Shaikhibrahim Z, Vogel W, Bohm D, Scheble V, et al.: ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer—a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis 2012, 15:165-169.
• [47]Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, et al.: Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009, 125:353-355.
• [48]Kroeze LI, van der Reijden BA, Jansen JH: 5-hydroxymethylcytosine: an epigenetic mark frequently deregulated in cancer. Biochim Biophys Acta 1855, 2015:144-154.
• [49]Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, et al.: Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008, 9:342-351.
• [50]Kang KA, Piao MJ, Kim KC, Kang HK, Chang WY, Park IC, et al.: Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation. Cell Death Dis 2014, 5:e1183.
• [51]Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, et al.: TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Rep 2014, 7:1343-1352.
• [52]Tsai YP, Chen HF, Chen SY, Cheng WC, Wang HW, Shen ZJ, et al.: TET1 regulates hypoxia-induced epithelial-mesenchymal transition by acting as a co-activator. Genome Biol 2014, 15:513. BioMed Central Full Text
• [53]Zhu Y, Qiu P, Ji Y: TCGA-assembler: open-source software for retrieving and processing TCGA data. Nat Methods 2014, 11:599-600.
• [54]Zhu Y, Xu Y, Helseth Jr DL, Gulukota K, Yang S, Pesce LL, et al. Zodiac: a comprehensive depiction of genetic interactions in cancer by integrating TCGA data. J Natl Cancer Inst. 2015;107.
• [55]Long Q, Xu J, Osunkoya AO, Sannigrahi S, Johnson BA, Zhou W, et al.: Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res 2014, 74:3228-3237.
• [56]Adamo P, Ladomery MR. The oncogene ERG: a key factor in prostate cancer. Oncogene. 2015.
• [57]Burdova A, Bouchal J, Tavandzis S, Kolar Z: TMPRSS2-ERG gene fusion in prostate cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslovakia 2014, 158:502-510.
• [58]Yardimci H, Zhang Y: Charting oxidized methylcytosines at base resolution. Nat Struct Mol Biol 2015, 22:656-661.
• [59]Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Committee IG: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005, 29:1228-1242.
• [60]Sorensen KD, Abildgaard MO, Haldrup C, Ulhoi BP, Kristensen H, Strand S, et al.: Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer. Br J Cancer 2013, 108:420-428.